April 22, 2015 / B3C newswire / -- XstalBio Ltd, a leading biologic formulation and drug-delivery company, today announced it has commenced work on an €9.3M EU Funded Horizon 2020 project to develop vaccines that protect cattle, sheep and poultry, against infection by parasites. The 4 year “PARAGONE” collaboration involves 17 partners from Europe, Uruguay and China and will aim to move several candidate vaccines from the laboratory into practical field trials. XstalBio, as the formulation and delivery partner will utilise its proprietary technology to bind antigens and immunostimulants together into vaccine microparticles that function as “inorganic pathogens”, with the aim of improving delivery and obtaining better, more targeted, protection against parasite infections. The vaccine microparticle technology that underpins this project is covered by the recently issued US Patent US8697133 “Slow Release Compositions”. XstalBio microparticle formulations are thermally stable so any vaccines produced will be suitable for use in developing countries where retention of the cold-chain is challenging.
Vaccine approaches are urgently being sought worldwide because livestock parasites, such as helminths, are becoming increasingly resistant to conventional drugs and if not controlled can significantly compromise the health of animals and result in major losses in productivity. Vaccines offer a safe and sustainable solution that will also addresses consumer concerns over drug residues in the food chain. The PARAGONE project has been coordinated by the Moredun Research Institute based in Scotland and brings together most of the major research groups in Europe working on parasite vaccines.
XstalBio CEO, Dr. Marie Claire Parker commented that “We are very pleased that XstalBio was chosen as the vaccine formulation partner in this world-leading consortium and look forward to our microparticle delivery technology making an important contribution to the success of the project. Control of parasites is a global problem affecting human as well as animal health and this development project will lead to other important applications of our vaccine technology.”
To discuss any of XstalBio’s proprietary technologies for formulation, stabilization, delivery or reconstitution of biologics, please contact us at: This email address is being protected from spambots. You need JavaScript enabled to view it., visit www.xstalbio.com, or talk to us by calling +44 141 330 3801.
About XstalBio
XstalBio is a privately-held company founded in 2004 and based in Glasgow, Scotland. XstalBio works collaboratively with international clients to help drive biopharmaceuticals and vaccines to market by enabling delivery of products to patients. XstalBio provides its experience, innovative technologies and expert consultancy to find efficient solutions to complex bioformulation challenges and accelerate the development of biologics.
XstalBio has successfully formulated over 50 therapeutic biologic entities and antigens working with many of the world’s top pharmaceutical and biotechnology companies as well as leading vaccine and animal health companies. APIs include mAbs, mAb fragments, cytokines, hormones, plasmids and peptides spanning a broad range of molecular weights and physical characteristics. In addition XstalBio has generated novel adjuvant formulations of many types of antigens including recombinant proteins, bacterial lysates, toxoids and polysaccharides. XstalBio scientists routinely take-on challenging formulation issues and seek to solve them by applying innovative, straightforward and scalable formulation technologies. The company has an excellent track-record for meeting milestones and moving forward with clients as their biopharmaceutical product challenges progress or change.
Paragone Partners
| List of participants Moredun Research Institute XstalBio Ltd Benchmark Animal Health Ltd Queens University Belfast The Royal Veterinary College-University of London Fios Genomics Ltd Ghent University Zoetis-Belgium Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences ImmunoTools GmbH Dublin City University University College Dublin Norwegian Veterinary Institute Agencia Estatal Consejo Superior de Investigaciones Científicas Universidad de Las Palmas de Gran Canaria University of Cordoba Universidad de la República |
Country UK UK UK UK UK UK Belgium Belgium China Germany Ireland Ireland Norway Spain Spain Spain Uruguay |
Contact
Dr. Marie Claire Parker
+44 141 330 3801
This email address is being protected from spambots. You need JavaScript enabled to view it.